Cefoperazone disk diffusion test and minimum inhibitory concentration comparison studies were performed on 421 recent bacterial isolates, using 30-and 75-pug commercially prepared disks. Acceptable correlation coefficients (-0.82 to -0.86) and very major (false-susceptible) interpretive error rates (<1%) were obtained with both disk concentrations. The interpretive criteria for both disks were identical. Using the preferred 75-,ug disk, the Thornsberry et al. criteria (J. Clin. Microbiol. 15:769-776, 1982) of >18 mm = susceptible (-32 ,ug/ml) and -14 mm = resistant (>64 ,u.g/ml) resulted in only 5.5% of strains having indeterminaterange zone diameters; the 30-Sg disk had 6.9% of strains with indeterminate zone diameters. The 75-p,g disk, excluding the testing of enterococci, minimized the very major and other interpretive errors to <5%. Larger zone diameters will contribute few technical problems with either disk concentration. Data from 1,320 zone diameters submitted for each quality control strain indicated no significant (P > 0.05) difference between disks made by the three major manufacturers, and consistent results were obtained within each laboratory with numerous lots of Mueller-Hinton agar (except for one manufacturer). Individual daily test and accuracy quality control ranges were calculated from clinical investigator laboratory data at 16 hospitals based on mean zone sizes and from an additional 8 laboratories with both mean and median calculations. The quality control data were nearly identical, and ranges calculated by the two methods were very similar. Susceptibility tests of Pseudomonas aeruginosa indicate that the cefoperazone disk or minimum inhibitory concentration test would accurately predict P. aeruginosa susceptibility test results for other pseudomonas-active cephalosporins (cefsulodin and ceftazidime), thus producing no very major interpretive errors.
pared cefoperazone 30-and 75-,ug disk zone diameters with the reference cefoperazone minimum inhibitory concentrations (MICs) as determined in divalent cation-supplemented MuellerHinton broth (21) . These results were compared with those published by Thornsberry and colleagues and by Welch et al. (29, 33) . Additional quality control parameters for both cefoperazone disk concentrations were established by multilaboratory clinical trials, using numerous disk and agar media preparations. Cross-resistance studies compared cefoperazone with the other cephalosporins (cefsulodin and ceftazidime) active against P. aeruginosa and correlated discrepant results with beta-lactamase hydrolysis of the substrates.
MATERIALS AND METHODS
Antimicrobial agetiis and media. Cefoperazone and carbenicillin were obtained from Pfizer Inc., New York, N.Y., and the cefoperazone 30-and 75-,ug disks were from B3BL Microbiology Systems, Cockeysville, Md. The cefsulodin powder was provided by Abbott Laboratories, North Chicago, Ill.; the ceftazidime and nitrocefin were provided by Glaxo Research Group Limited, Greenford, UJ.K.; and PADAC (pyridine-2-azo-p-dimethylaniline cephalosporin) was from Hoechst-Roussel Pharmaceuticals, Inc., Somerville, N.J. All compounds were diluted in divalent cation (25 mg of niagnesium and 50 mg of calcium per liter)-supplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) (21) . A 16-dilution schedule was utilized for each drug, ranging from 0.008 and 256 ,ug/ ml.
For the disk zone quality control study, three lots of 30-and 75-,ug cefoperazone disks were used, one each from BBL, Difco, and Pfizer (Groton, Conn.). All lots had assayed potencies ranging from 97 to 122% of target value by microbiological assays. The potency range for UV methods was 90 to 120%.
Bacterial strains. The organisms used for the regression line phase of the studies were 421 isolates collected from the clinical microbiology laboratories of the collaborating investigators and others contributed by P. C. Fuchs investigators. The total number of zones reported for each disk and control organism was 1,320. These data were statistically analyzed to detecting variation in the disk lots (six), agar lots (nine from four sources), or investigator by methods previously described (9, 20) .
Clinical investigators contributing in vitro studies to Pfizer Inc. used the NCCLS disk method, 75-,g cefoperazone disks, and the three recommended quality control organisms (20) . These data (16 hospitals) were pooled from the quality control strains and statistically analyzed by commonly used computer programs (9) . No common lot of agar was used in this phase to monitor interlaboratory variations.
Antibiotic (4, 20) . These data were compared with the MICs by the method of least squares as adapted to computers and the techniques described by Metzler and DeHaan (19) .
Beta-lactamase hydrolysis test were performed with chromogenic cephalosporin substrates (nitrocefin and PAIAC), and resultant data were correlated to MICs for cefoperazone, cefsulodin, and ceftazidime obtained by standardized methods (25, 27) . UV spectrophotometric procedures have been previously described (11) . RESULTS
The cefoperazone disk diffusion test regression line studies were performed on 421 recent are found in Fig. 1 (29) . In Fig. 1 (75-,ug disk) the short-interval regression line of 2.0 to 256 pug/ml correlates well with the previously established criteria, using a correlative susceptible cefoperazone MIC of c32 ,ug/ml and a resistant concentration of >64 ,ug/ml. The interpretive error rates would be: very major (false-susceptible) = 0.95%; major (false-resistant) = 0.23%; and minor error = 5.46%. Figure  2 presents the 30-,ug cefoperazone disk statistics, including three regression lines and two interpretive criteria sets. Using <16 ,ug/ml as the susceptible cefoperazone level, the cefoperazone 30-,ug disk may be used with some confidence. (12) . Table 2 presents the results of two investigations of quality control for the standardized disk diffusion test (20) . In an eight-laboratory controlled trial, methods were used as described by the NCCLS (20) and the study structure was as reported previously by Gavan et al. (9) . The data from 1,320 zone diameters were submitted for each quality control strain and cefoperazone disk potency. No significant (P > 0.05) difference was encountered between disks manufactured by each of three companies. On a common lot of agar (Difco dry powder, lot 675407), participants had statistically similar results; thus, technical variation was considered minimal. Yet, two participants using agar from the same manufacturer (Oxoid Ltd., London, U.K.) reported zone diameters different from those submitted by other laboratories using Difco, BBL, and GIBCO Diagnostics (Madison, Wis.) Mueller-Hinton agars. The statistical analysis of all 1,320 zones for each disk concentration provided mean and median zones 1 mm different from those calculated after excluding data from participants using Oxoid agar. The individual daily test and accuracy control ranges calculated by the Gavan et al. method of medians and those computed with the more conventional mean + 2 standard deviations method were nearly identical. These recommendations were further confirmed by the submitted quality control zones from 16 hospitals also contributing cefoperazone in vitro studies to Pfizer Inc. At the time of writing, at least 818 zones were reported for each NCCLS quality control strain. The mean zone + standard deviation of each were as VOL. 15, 1982 on October 26, 2017 by guest http://jcm.asm.org/ Table 2 ). Previously published cross-resistance studies of cefoperazone and currently marketed cephalosporins such as cephalothin, cefamandole, and cefoxitin demonstrated the need for a separate disk or susceptibility test (29) . The slight but significantly greater susceptibility of cefoperazone to Enterobacteriaceae beta-lactamase compared with cefotaxime-like methoximino cephalosporins or moxalactam also indicates a need for separate testing (C. Thornsberry, Drugs, in press). Here we present (Table 3) cross-resistance data for cefoperazone and the other two antipseudomonas cephalosporins, ceftazidime and cefsulodin. At least 93.7% total interpretive agreement was found among all three drugs. Only four strains were resistant to one or more of these cephalosporins. Of the six organisms that were resistant or indeterminate to cefoperazone, two were susceptible to cefsulodin inhibition. However, four isolates were susceptible (MICs, 2.0 to 8.0 ,ugIml) to ceftazidime. The six strains were subjected to betalactamase hydrolysis studies. Results of these studies indicate that five of the six strains produced beta-lactamase as detected by chromogenic cephalosporin reagents (25, 27 Antimicrob. Chemother., in press). DISCUSSION Cefoperazone possesses well-documented antimicrobial activity against the Enterobacteriaceae, staphylococci, non-enterococcal Streptococcus spp., P. aeruginosa, Haemophilus spp., Neisseria spp., and some anaerobes (1, 6, 12, 15, 17, 23, (29) (30) (31) (32) (33) . This spectrum of inhibition is significantly superior to cephalothin, cefoxitin, and cefamandole to support the need for separate susceptibility testing (29 (29, 33) . These studies have used several disk concentrations to formalize sets of tentative standards for the 30-and 75-,ug disks. The human pharmacology and ultimate choice of the susceptible cefoperazone MIC correlate have a critical bearing on the ultimate decision.
The correlation of cefoperazone human pharmacokinetics, susceptible MIC criteria, proposed interpretive zone diameters (20, 29) , and interpretive error rates is found in Table 4 . Two proposed intravenous dose schedules produce high and prolonged cefoperazone serum concentrations that are in excess of several possible susceptible MICs for 25 to 75% of the dose interval (2, 5, 18, 28) . Similarly, cefamandole and cefotaxime have levels above their susceptible MICs for 30 to 45% of the dose interval.
However, the latter two drugs require more frequent infusions and generally larger daily doses to achieve statistics comparable to that of cefoperazone. The s16-and s32-,ug/ml susceptible breakpoints are those previously cited by Thornsberry et al., and the lower <8.0-.g/tIl level is a new data treatment for comparison with cefamandole and cefotaxime (8, 20, 29) . The disk interpretive zones suggested here and by others result in very acceptable error rates, with only the cefamandole 30-,xg disk having >1% false-susceptibles (8, 20, 29, 33) . The cefoperazone blood levels with 2-and 1-g intravenous infusions appear to support MIC susceptible correlates for s32 and s16 ,ug/ml, respectively (2, 5, 18, 28 Cross-resistance studies of 69 P. aeruginosa strains revealed an incomplete predictibility between those cephalosporins active against this species. Beta-lactamase hydrolysis studies demonstrated cefoperazone and cefsulodin to be most labile to the beta-lactamases produced by some strains of P. aeruginosa. Ceftazidime was most stable, yet two strains had ceftazidime MICs of .32 ,ug/ml, probably due to decreased drug access to cell target sites. The frequency of occurrence of these resistances will depend upon the endemic P. aeruginosa populations in any geographic area or hospital. An analysis of a large sample of P. aeruginosa strains from different geographic areas showed only 7 and 4.2% resistance to cefoperazone and ceftazidime, respectively (12; Jones et al., in press). The use of the cefoperazone MIC or disk diffusion test result to predict cefsulodin or ceftazidime susceptibility might be considered since significant false susceptibility results were not produced. The few cefoperazone-resistant P. aeruginosa strains could then be tested by a specific cefsulodin or ceftazidime test if treatment with these agents were still being considered. Only ceftazidime has a usable spectrum against Pseudomonas spp. other than P. aeruginosa (16, 24, 31, 32) .
We believe that the beta-lactamases produced .64 Ixg/ml or resistant. Challenge Enterobacteriaceae strains known to produce type III-TEM beta-lactamases were used to establish these interpretive criteria. All of the isolates (10 from two species) were resistant by disk diffusion and broth dilution tests.
In conclusion, the cefoperazone disk test interpretive criteria with the 30-and 75-,ug disks seem to be well established. Recommendations for use of each disk content are identical (-18 mm = susceptible and <14 mm = resistant), but the correlate MICs differ by one log2 dilution step. We prefer to use the 75-,ug disk if dosages of 2 g/12 h are used routinely or 30-Rxg disks if lower dosages are used. In either case, enterococci should not be tested, thus minimizing very major and other errors to <5%. Also, quality control performance ranges have been determined in structured interlaboratory trials and by in-use data from clinical investigators. Lastly, the cross-resistance analyses presented earlier (29) and in this paper favor the use of a separate cefoperazone disk for testing Enterobacteriaceae, gram-positive cocci, and P. aeruginosa. The cefoperazone susceptibility results against P. aeruginosa may be used for cefsulodin and ceftazidime susceptibility. Of the three antipseudomonas drugs, cefoperazone was least active, and thus it is the most appropriate representative for in vitro testing (i.e. minimal number of false-susceptible results produced). Cefoperazone should be a welcome therapeutic addition for treatment of a wide variety of serious infections, and the in vitro tests of its susceptibility appear to be ready for clinical laboratory application. 
